B+
Bull case
25%
Probability
Target price
$7.25
+232.6% vs current
BDTX
Black Diamond TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.50
+60.6% vs current
B-
Bear case
25%
Probability
Target price
$1.10
-49.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Primary-source evidence is strong, but this remains a low-coverage biotech with limited analyst confirmation. The May 21 Phase 2 update is the main positive driver, while the 10-Q supports runway visibility; however, the packet does not provide a reliable post-print market-reaction series or fresh analyst revisions, so this should stay a monitoring-style report rather than a conviction upgrade.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-21eventPositive Phase 2 silevertinib readout in frontline EGFR non-classical NSCLCHigh impact
The May 21 8-K reported positive Phase 2 data in 43 frontline NSCLC patients with EGFR non-classical mutations, including preliminary median PFS of 15.2 months, DOR not reached, 60% ORR, 91% DCR, no new safety signals, and management said the data support 150 mg QD for pivotal development [#8-K-2026-05-21].
2028-12-31catalystCash runway into 2H 2028 reduces immediate financing pressureMedium impact
The Q1 2026 10-Q says cash, cash equivalents and investments were approximately $118.3 million as of March 31, 2026 and that the company expects this to fund operating expenses and capex into the second half of 2028, which lowers near-term dilution pressure even though additional capital will likely still be needed beyond that window [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology